Chimeric antigen receptor (CAR) T cells specific for an antigen, BCMA, have shown efficacy in controlling multiple myeloma in some patients, but responses vary. Here the authors show that, by over-expressing a granzyme B-NOXA fusion protein in anti-BCMA CAR T cells, cancer cells are rendered more susceptible to apoptosis induction and CAR T-mediated killing.
- Thomas Kimman
- Marta Cuenca
- Victor Peperzak